SUMO-primed ubiquitylation to treat cancer and neuro disorders
Approved tumor therapeutics leverage small ubiquitin-related modifier (SUMO)-targeted ubiquitin signaling to generate distinct SUMO-ubiquitin topologies for inactivating and eliminating oncoproteins.
Proximity-inducing recruitment of E3 SUMO ligases by SUMO-targeting chimeras opens a future therapeutic avenue to inactivate oncogenic transcription factors.
Proximity-inducing recruitment of aggregation-prone proteins to PML nuclear bodies represents a prospective SUMO-based therapeutic modality in neurodegenerative disease.
https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(25)00205-6
